UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other  Cancer Subpopulation (NASDAQ:URGN)

PDUFA date of June 13th 2025 by which FDA will decide upon whether or not UGN-102 should be approved for patients with recurrent low-grade intermediate-risk...